Condition
Stage IA Uterine Sarcoma
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
100.0%
2 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
2 of 0 completed with results
Key Signals
2 with results0
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Terminated2
Clinical Trials (2)
Showing 2 of 2 trials
NCT01367301Not ApplicableTerminatedPrimary
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
NCT01958580Not ApplicableTerminatedPrimary
Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery
Showing all 2 trials